<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964947</url>
  </required_header>
  <id_info>
    <org_study_id>65241</org_study_id>
    <secondary_id>GRANT13200494</secondary_id>
    <nct_id>NCT04964947</nct_id>
  </id_info>
  <brief_title>Tobramycin Injection to Prevent Infection in Open Fractures</brief_title>
  <official_title>Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arun Aneja</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of open extremity fracture (OEF) treatment is to promote fracture healing and&#xD;
      restore function while preventing the development of infection. This is achieved through&#xD;
      systematic and timely wound debridement and irrigation, fracture stabilization, tetanus&#xD;
      prophylaxis, systemic and local antimicrobial therapy, and judicious timing of wound closure&#xD;
      based on cleanliness. Early prophylactic systemic antibiotics lower infection rates in open&#xD;
      fractures but have limitations of achieving adequate concentration at the hypoperfused wound&#xD;
      area. OEF wounds are frequently poor in vasculature secondary to the soft tissue injury,&#xD;
      hence adequate concentration of antibiotic cannot permeate to the tissue at risk. If systemic&#xD;
      antibiotic concentrations are increased to achieve minimum inhibitory concentration (MIC) for&#xD;
      pathogens at the wound, there is heightened concern for systemic drug toxicity. In sharp&#xD;
      contrast, locally administered antibiotics achieve high drug concentration directly within&#xD;
      the wound cavity with minimal systemic side effects. Local antibiotic therapy has shown to&#xD;
      reduce rates of open fracture wound infection. With the serious implications of postoperative&#xD;
      infections in OEF, it is imperative that all measures including further use of prophylactic&#xD;
      local antibiotics be considered to prevent fracture-related infection (FRI). The overarching&#xD;
      hypothesis for this project is that a novel synergistic combination of local aqueous&#xD;
      tobramycin plus perioperative weight-based IV cephalosporin antibiotic prophylaxis will&#xD;
      reduce the rate of FRI one year after OEF surgery. This in turn will improve OEF patient&#xD;
      outcomes, decreasing morbidity and return to the operating room (OR) without any adverse&#xD;
      effect on fracture healing. Regardless of the treatment group, bacterial speciation will be&#xD;
      determined for patients that do develop FRI to help guide future treatment. The goal is to&#xD;
      improve the clinical outcome and recovery of the population that sustains an OEF by&#xD;
      decreasing the rate of FRI and fracture nonunions while concurrently educating on bacterial&#xD;
      speciation and resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of infection one year after open fracture fixation surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tobramycin effects on non-union</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Modified radiographic union score for tibial fracture (mRUST) scores combined with clinical observation of functional weight bearing at 3 months will be assessed. If union status remains unclear, nonunion will be further defined as a need for secondary bone grafting or surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobramycin effects on non-union</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Modified radiographic union score for tibial fracture (mRUST) scores combined with clinical observation of functional weight bearing at 6 months will be assessed. If union status remains unclear, nonunion will be further defined as a need for secondary bone grafting or surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobramycin effects on non-union</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Modified radiographic union score for tibial fracture (mRUST) scores combined with clinical observation of functional weight bearing at 12 months will be assessed. If union status remains unclear, nonunion will be further defined as a need for secondary bone grafting or surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in bacterial specification between treatment and placebo group.</measure>
    <time_frame>12 months</time_frame>
    <description>Upon identification of a fracture-related infection within the first 12 months following surgical fixation, sterile intraoperative cultures will be obtained and grown over 21 days to determine bacterial speciation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in antibiotic resistance between treatment and placebo group.</measure>
    <time_frame>12 months</time_frame>
    <description>Upon identification of a fracture-related infection within the first 12 months following surgical fixation, sterile intraoperative cultures will be obtained and grown over 21 days to determine antimicrobial resistance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Wound Infection</condition>
  <condition>Fractures, Open</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Tobramycin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group receive a placebo injection plus standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin Injection</intervention_name>
    <description>80 milligrams of tobramycin diluted in 40 milliliters of normal saline</description>
    <arm_group_label>Tobramycin Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>40 milliliters of normal saline</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Tobramycin Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Open fracture to arm, leg, or both&#xD;
&#xD;
          -  Over the age of 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 18&#xD;
&#xD;
          -  Allergy to tobramycin or any other antibiotic in the aminoglycoside family&#xD;
&#xD;
          -  Previously treated with a resorbable antibiotic carrier&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Aneja, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arun Aneja, MD, PhD</last_name>
    <phone>859-323-5533</phone>
    <email>arun.aneja@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Kavolus, MD</last_name>
    <phone>859-323-5533</phone>
    <email>mwkavolus@uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arun Aneja, MD, PhD</last_name>
      <phone>859-323-5533</phone>
      <email>arun.aneja@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Arun Aneja</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Local antibiotic</keyword>
  <keyword>Non-union</keyword>
  <keyword>Aminoglycoside</keyword>
  <keyword>Tobramycin</keyword>
  <keyword>Open extremity fracture</keyword>
  <keyword>fracture related infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

